Rani Therapeutics Holdings (RANI) Common Equity (2020 - 2026)

Rani Therapeutics Holdings' Common Equity history runs 7 years deep, the most recent figure standing at $28.4 million for Q1 2026.

• On a quarterly basis, Common Equity rose 631.03% year-over-year to $28.4 million in Q1 2026; TTM through Mar 2026 was $28.4 million, a 631.03% increase from a year earlier, with the FY2025 full-year figure at $33.0 million, up 845.03% from the prior year.
• Common Equity retreated to $28.4 million in Q1 2026 per RANI's latest filing, from $33.0 million in the prior quarter.
• Across five years, Common Equity topped out at $110.6 million in Q1 2022 and bottomed at -$12.0 million in Q3 2025.
• The 5-year median for Common Equity is $28.4 million (2026), against an average of $35.5 million.
• Biggest YoY gain for Common Equity was 845.03% in 2025; the steepest drop was 307.32% in 2025.
• Year by year, Common Equity stood at $74.0 million in 2022, then tumbled by 65.62% to $25.4 million in 2023, then plunged by 86.27% to $3.5 million in 2024, then soared by 845.03% to $33.0 million in 2025, then declined by 13.95% to $28.4 million in 2026.
• Per Business Quant, the three latest RANI Common Equity figures stand at $28.4 million (Q1 2026), $33.0 million (Q4 2025), and -$12.0 million (Q3 2025).